NextCure, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NXTC Nasdaq 2836 www.nextcure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NextCure, Inc.

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 2:01 pm
Sector Update: Healthcare Stocks Fall Late Afternoon - Jul 14th, 2026 1:46 pm
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill - Jul 14th, 2026 6:00 am
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy - Jul 14th, 2026 4:00 am
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - Jun 4th, 2026 6:00 am
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - Jun 1st, 2026 6:00 am
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - May 7th, 2026 2:05 pm
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - May 4th, 2026 5:05 am
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - Apr 21st, 2026 8:15 am
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Apr 7th, 2026 6:05 am
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - Mar 31st, 2026 2:05 pm
NextCure Provides Business Update - Jan 23rd, 2026 5:00 am